{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-11T06:46:36.420505+00:00","company":{"ticker":"NPCE","cik":1528287,"company_name":"NeuroPace Inc"},"pagination":{"limit":100,"returned":33,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"CRG Servicing LLC","detail":"credit_facility","count":1,"first_seen":"2024-05-08T23:59:59+00:00","last_seen":"2024-05-08T23:59:59+00:00","evidence_fact_ids":[50898]},{"display_name":"Rapport Therapeutics, Inc.","detail":"collaboration","count":1,"first_seen":"2023-12-04T23:59:59+00:00","last_seen":"2023-12-04T23:59:59+00:00","evidence_fact_ids":[90391]}],"lender":[{"display_name":"MidCap Funding IV Trust, as agent, and MidCap Financial Trust","detail":"credit_facility","count":1,"first_seen":"2025-06-04T23:59:59+00:00","last_seen":"2025-06-04T23:59:59+00:00","evidence_fact_ids":[45875]}]},"facts":[{"fact_type":"shareholder_vote","fact_key":"3c4a3c795d73b7fd4ebe3a27feab78e2bd8eb324","cik":1528287,"ticker":"NPCE","company_name":"NeuroPace Inc","filed_at":"2026-06-08T20:54:11+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-05","outcome":"passed","proposal_text":"Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2026","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"—","subject":null,"votes_abstain":"207,310","votes_against":"209,301","votes_for":"28,850,105","votes_withheld":null}]},"claim":"NeuroPace Inc shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-05 meeting.","evidence_excerpt":"Proposal 2 - Ratification of Independent Registered Public Accounting Firm . NeuroPace’s stockholders ratified the appointment of PricewaterhouseCoopers LLP as NeuroPace’s independent registered public accounting firm for the fiscal year ending December 31, 2026.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-261965","anchor_url":"https://secwatch.observer/filing/0001193125-26-261965#claim-3c4a3c795d73b7fd4ebe3a27feab78e2bd8eb324","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1528287/000119312526261965/0001193125-26-261965-index.htm"},{"fact_type":"shareholder_vote","fact_key":"d95477ae13967ef0d63df3bc596c61c2b7f4c004","cik":1528287,"ticker":"NPCE","company_name":"NeuroPace Inc","filed_at":"2026-06-08T20:54:11+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-05","outcome":"passed","proposal_text":"Election of Class II directors","proposal_type":"director_election","results":[{"broker_non_votes":"8,048,133","subject":"Lisa Andrade","votes_abstain":null,"votes_against":null,"votes_for":"15,194,450","votes_withheld":"6,024,133"},{"broker_non_votes":"8,048,133","subject":"Scott Huennekens","votes_abstain":null,"votes_against":null,"votes_for":"20,973,382","votes_withheld":"245,201"}]},"claim":"NeuroPace Inc shareholders approved Election of Class II directors at the 2026-06-05 meeting.","evidence_excerpt":"Proposal 1 - Election of Directors . NeuroPace’s stockholders elected each of the following Class II director nominees to hold office until NeuroPace’s 2029 Annual Meeting of Stockholders and until their successor is duly elected and qualified or until their earlier death, resignation or removal.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-261965","anchor_url":"https://secwatch.observer/filing/0001193125-26-261965#claim-d95477ae13967ef0d63df3bc596c61c2b7f4c004","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1528287/000119312526261965/0001193125-26-261965-index.htm"},{"fact_type":"earnings_release","fact_key":"2f08b524a3e2c0d0f99b2f7406428082dac93f44","cik":1528287,"ticker":"NPCE","company_name":"NeuroPace Inc","filed_at":"2026-05-12T20:07:17+00:00","payload":{"eps_text":null,"guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":"($6.7) million","period_text":"first quarter ended March 31, 2026","report_date":"2026-05-12","result_type":"reported_results","revenue_text":"Total revenue of $22.1 million"},"claim":"NeuroPace Inc reported first quarter ended March 31, 2026 results: revenue Total revenue of $22.1 million, net income ($6.7) million. Guidance raised.","evidence_excerpt":"forth by specific reference in such filing. \n\n--- EX-99 (EX-99.1) ---\n\nNeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance Total revenue of $22.1 million Raises full year 2026 guidance to $99 million to $101 million, up from $98 million to $100 million previously Assumes 21% to 23% growth in core RNS ® revenue from existing","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001528287-26-000019","anchor_url":"https://secwatch.observer/filing/0001528287-26-000019#claim-2f08b524a3e2c0d0f99b2f7406428082dac93f44","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1528287/000152828726000019/0001528287-26-000019-index.htm"},{"fact_type":"executive_change","fact_key":"50d5013fd0","cik":1528287,"ticker":"NPCE","company_name":"NeuroPace Inc","filed_at":"2025-06-24T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-06-20","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Patrick F. Williams was appointed as Chief Financial Officer at NeuroPace Inc.","evidence_excerpt":"the Company has appointed Patrick F. Williams as Chief Financial Officer, effective as of the Transition Date.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-145738","anchor_url":"https://secwatch.observer/filing/0001193125-25-145738#claim-50d5013fd0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1528287/000119312525145738/0001193125-25-145738-index.htm"},{"fact_type":"executive_change","fact_key":"8788933df9","cik":1528287,"ticker":"NPCE","company_name":"NeuroPace Inc","filed_at":"2025-06-24T23:59:59+00:00","payload":{"action":"resigned","action_category":"role_change","departure_tone":"routine","effective_date":"2025-06-20","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":"Patrick F. Williams","successor_named":true},"claim":"Rebecca Kuhn resigned as Chief Financial Officer at NeuroPace Inc.","evidence_excerpt":"On June 20, 2025, Rebecca Kuhn departed from her position as Chief Financial Officer and Vice President, Finance and Administration of NeuroPace, Inc.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-145738","anchor_url":"https://secwatch.observer/filing/0001193125-25-145738#claim-8788933df9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1528287/000119312525145738/0001193125-25-145738-index.htm"},{"fact_type":"debt_financing","fact_key":"525ffbe340c4303737591368b3a6cbbefad77d9d","cik":1528287,"ticker":"NPCE","company_name":"NeuroPace Inc","filed_at":"2025-06-04T23:59:59+00:00","payload":{"counterparty":"MidCap Funding IV Trust, as agent, and MidCap Financial Trust, as term loan servicer","effective_date":"2025-06-04","event":"incurrence","instrument_type":"credit_facility","interest_rate_text":"SOFR plus a margin of 5.50% (subject to SOFR floor of 2.00%) for the Term Loan a","item_codes_triggered":["2.03"],"maturity_text":"June 4, 2030","principal_text":"$60 million term loan facility and a $15 million commitment amount for an asset-based revolving credit facility"},"claim":"NeuroPace Inc incurred credit facility of $60 million term loan facility and a $15 million commitment amount for an asset-based revolving credit facility with MidCap Funding IV Trust, as agent, and MidCap Financial Trust, as term loan servicer at SOFR plus a margin of 5.50% (subject to SOFR floor of 2.00%) for the Term Loan a maturing June 4, 2030.","evidence_excerpt":"On June 4, 2025 (the “Closing Date”), NeuroPace, Inc. (the “Company”) entered into a credit, security and guaranty agreement (the “Credit Agreement”) by and among the Company, MidCap Funding IV Trust, as agent, MidCap Financial Trust, as term loan servicer and the financial institutions and other entities from time to time party thereto. The Credit Agreement provides for a first lien senior secured credit facility consisting of (i) a $60 million term loan facility, which was funded at closing of the Credit Agreement (the “Term Loan”); and (ii) an asset-based revolving credit facility in an aggregate principal amount not to exceed the lesser of (A) a $15 million commitment amount and (B) the available borrowing base under the Credit Agreement (the “Revolver,” and together with the Term Loan, the “Loans”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-25-134946","anchor_url":"https://secwatch.observer/filing/0001193125-25-134946#claim-525ffbe340c4303737591368b3a6cbbefad77d9d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1528287/000119312525134946/0001193125-25-134946-index.htm"},{"fact_type":"executive_change","fact_key":"d0359afa20","cik":1528287,"ticker":"NPCE","company_name":"NeuroPace Inc","filed_at":"2025-01-08T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-01-06","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Scott Huennekens was appointed as Director at NeuroPace Inc.","evidence_excerpt":"appointed Scott Huennekens as a director to fill the newly created vacancy, effective as of January 6, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-003547","anchor_url":"https://secwatch.observer/filing/0001193125-25-003547#claim-d0359afa20","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1528287/000119312525003547/0001193125-25-003547-index.htm"},{"fact_type":"earnings_release","fact_key":"9edbe6b9ccb86259b4e13e4dbefdb023f1f0d5b9","cik":1528287,"ticker":"NPCE","company_name":"NeuroPace Inc","filed_at":"2024-05-08T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"Net loss was $8.9 million","period_text":"the first quarter ended March 31, 2024","report_date":"2024-05-08","result_type":"reported_results","revenue_text":"$18.1 million"},"claim":"NeuroPace Inc reported the first quarter ended March 31, 2024 results: revenue $18.1 million, net income Net loss was $8.9 million. Guidance reaffirmed.","evidence_excerpt":"by specific reference in such filing. \n\n--- EX-99.1 (EX-99.1) ---\n\nNeuroPace Reports First Quarter 2024 Financial Results and Provides Corporate Update Revenue increased to $18.1 million in Q1 2024, a 25% increase over Q1 2023 Extended the maturity date of the Company's term loan by one year to September 30, 2026 Maintained full-year 2024 revenue guidance of $73","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001528287-24-000010","anchor_url":"https://secwatch.observer/filing/0001528287-24-000010#claim-9edbe6b9ccb86259b4e13e4dbefdb023f1f0d5b9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1528287/000152828724000010/0001528287-24-000010-index.htm"},{"fact_type":"material_agreement","fact_key":"3e783b37f13981562b94c803c9955385093c8f3d","cik":1528287,"ticker":"NPCE","company_name":"NeuroPace Inc","filed_at":"2024-05-08T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Amendment","agreement_type":"credit_facility","counterparty":"CRG Servicing LLC, as administrative agent and collateral agent for the lenders","effective_date":"2024-05-02","item_codes_triggered":["1.01"],"value_text":null},"claim":"NeuroPace Inc amended Amendment with CRG Servicing LLC, as administrative agent and collateral agent for the lenders (effective 2024-05-02).","evidence_excerpt":"On May 2, 2024, NeuroPace, Inc. (the “Company”) entered into an amendment (the “Amendment”) to the Company’s existing Term Loan Agreement, dated as of September 24, 2020 (as amended from time to time, the “Loan Agreement”), with the lenders party to the Loan Agreement and CRG Servicing LLC, as administrative agent and collateral agent for the lenders.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001528287-24-000010","anchor_url":"https://secwatch.observer/filing/0001528287-24-000010#claim-3e783b37f13981562b94c803c9955385093c8f3d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1528287/000152828724000010/0001528287-24-000010-index.htm"},{"fact_type":"earnings_release","fact_key":"481907d75c4b1f67b455cb6166d616ae2da1f118","cik":1528287,"ticker":"NPCE","company_name":"NeuroPace Inc","filed_at":"2024-03-05T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"initiated","item_codes_triggered":["2.02"],"net_income_text":"$6.2 million","period_text":"fourth quarter and full year ended December 31, 2023","report_date":"2024-03-05","result_type":"reported_results","revenue_text":"$18.0 million"},"claim":"NeuroPace Inc reported fourth quarter and full year ended December 31, 2023 results: revenue $18.0 million, net income $6.2 million. Guidance initiated.","evidence_excerpt":"NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million Revenue increased to $18.0 million in Q4 2023","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001528287-24-000004","anchor_url":"https://secwatch.observer/filing/0001528287-24-000004#claim-481907d75c4b1f67b455cb6166d616ae2da1f118","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1528287/000152828724000004/0001528287-24-000004-index.htm"},{"fact_type":"executive_change","fact_key":"7bc2e3dcda","cik":1528287,"ticker":"NPCE","company_name":"NeuroPace Inc","filed_at":"2024-02-07T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-03-06","interim":false,"role":"Chief Legal Officer and Corporate Secretary","role_category":"general_counsel","successor_name":null,"successor_named":false},"claim":"Irina Ridley resigned as Chief Legal Officer and Corporate Secretary at NeuroPace Inc.","evidence_excerpt":"On February 1, 2024, Irina Ridley notified NeuroPace, Inc. (the “Company”) that she was resigning from her role as the Company’s Chief Legal Officer and Corporate Secretary and that her last day of employment will be March 6, 2024 (the “Separation Date”).","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001193125-24-026756","anchor_url":"https://secwatch.observer/filing/0001193125-24-026756#claim-7bc2e3dcda","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1528287/000119312524026756/0001193125-24-026756-index.htm"},{"fact_type":"earnings_release","fact_key":"e9f0eaf8f7ace1d62155ff947b15dfbda4b8f946","cik":1528287,"ticker":"NPCE","company_name":"NeuroPace Inc","filed_at":"2024-01-08T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fiscal quarter and year ended December 31, 2023","report_date":"2024-01-08","result_type":"preliminary_results","revenue_text":null},"claim":"NeuroPace Inc reported preliminary financial results for the fiscal quarter and year ended December 31, 2023.","evidence_excerpt":"On January 8, 2024, NeuroPace issued a press release announcing its preliminary unaudited revenue and cash balance for the fiscal quarter and year ended December 31, 2023, as well as providing a summary of business updates.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-24-003861","anchor_url":"https://secwatch.observer/filing/0001193125-24-003861#claim-e9f0eaf8f7ace1d62155ff947b15dfbda4b8f946","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1528287/000119312524003861/0001193125-24-003861-index.htm"},{"fact_type":"material_agreement","fact_key":"9b6739806d947d88b5960395c88ca883bc574eb6","cik":1528287,"ticker":"NPCE","company_name":"NeuroPace Inc","filed_at":"2023-12-04T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Agreement","agreement_type":"collaboration","counterparty":"Rapport Therapeutics, Inc.","effective_date":"2023-11-28","item_codes_triggered":["1.01"],"value_text":"approximately $3.7 million"},"claim":"NeuroPace Inc entered into Agreement with Rapport Therapeutics, Inc. valued at approximately $3.7 million (effective 2023-11-28).","evidence_excerpt":"On November 28, 2023 NeuroPace, Inc. entered into a collaboration agreement (“Agreement”) with Rapport Therapeutics, Inc. (“Rapport”), pursuant to which NeuroPace will provide certain site data for Rapport to use in targeting potential patients for their Phase 2a trial of their GAMA 8 Receptor-Associated Protein (“RAP”) compound","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-288474","anchor_url":"https://secwatch.observer/filing/0001193125-23-288474#claim-9b6739806d947d88b5960395c88ca883bc574eb6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1528287/000119312523288474/0001193125-23-288474-index.htm"},{"fact_type":"earnings_release","fact_key":"9997e086473aa1d16df647b1e563a759272375d1","cik":1528287,"ticker":"NPCE","company_name":"NeuroPace Inc","filed_at":"2023-11-06T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":"$(7.3 million)","period_text":"third quarter ended September 30, 2023","report_date":"2023-11-06","result_type":"reported_results","revenue_text":"$16.4 million"},"claim":"NeuroPace Inc reported third quarter ended September 30, 2023 results: revenue $16.4 million, net income $(7.3 million). Guidance raised.","evidence_excerpt":"NeuroPace Reports Third Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance Third quarter 2023 revenue of $16.4 million","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001528287-23-000040","anchor_url":"https://secwatch.observer/filing/0001528287-23-000040#claim-9997e086473aa1d16df647b1e563a759272375d1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1528287/000152828723000040/0001528287-23-000040-index.htm"},{"fact_type":"earnings_release","fact_key":"1f0c3bb57a2515a5a47236760a2a468f0b367594","cik":1528287,"ticker":"NPCE","company_name":"NeuroPace Inc","filed_at":"2023-08-08T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"full year 2023","report_date":"2023-08-08","result_type":"guidance_update","revenue_text":"$59 million to $61 million"},"claim":"NeuroPace Inc reported full year 2023 results: revenue $59 million to $61 million. Guidance raised.","evidence_excerpt":"Increased total revenue guidance to range between $59 million and $61 million","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001528287-23-000033","anchor_url":"https://secwatch.observer/filing/0001528287-23-000033#claim-1f0c3bb57a2515a5a47236760a2a468f0b367594","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1528287/000152828723000033/0001528287-23-000033-index.htm"},{"fact_type":"earnings_release","fact_key":"b769217bac2f8f4de409245834723e2eae2864c0","cik":1528287,"ticker":"NPCE","company_name":"NeuroPace Inc","filed_at":"2023-08-08T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$9.1 million","period_text":"the second quarter ended June 30, 2023","report_date":"2023-08-08","result_type":"reported_results","revenue_text":"$16.5 million"},"claim":"NeuroPace Inc reported the second quarter ended June 30, 2023 results: revenue $16.5 million, net income $9.1 million.","evidence_excerpt":"Total revenue was $16.5 million in the second quarter of 2023","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001528287-23-000033","anchor_url":"https://secwatch.observer/filing/0001528287-23-000033#claim-b769217bac2f8f4de409245834723e2eae2864c0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1528287/000152828723000033/0001528287-23-000033-index.htm"},{"fact_type":"executive_change","fact_key":"d8e684f43d","cik":1528287,"ticker":"NPCE","company_name":"NeuroPace Inc","filed_at":"2023-06-28T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-07-10","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Joel Becker was appointed as Director at NeuroPace Inc.","evidence_excerpt":"On June 28, 2023, NeuroPace appointed Joel Becker as Chief Executive Officer and as a member of the Board, in each case effective as of the Separation Date.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-177492","anchor_url":"https://secwatch.observer/filing/0001193125-23-177492#claim-d8e684f43d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1528287/000119312523177492/0001193125-23-177492-index.htm"},{"fact_type":"executive_change","fact_key":"ddc9879213","cik":1528287,"ticker":"NPCE","company_name":"NeuroPace Inc","filed_at":"2023-06-28T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-07-10","interim":false,"role":"Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Joel Becker was appointed as Chief Executive Officer at NeuroPace Inc.","evidence_excerpt":"On June 28, 2023, NeuroPace appointed Joel Becker as Chief Executive Officer and as a member of the Board, in each case effective as of the Separation Date.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-177492","anchor_url":"https://secwatch.observer/filing/0001193125-23-177492#claim-ddc9879213","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1528287/000119312523177492/0001193125-23-177492-index.htm"},{"fact_type":"executive_change","fact_key":"2c239bcc1c","cik":1528287,"ticker":"NPCE","company_name":"NeuroPace Inc","filed_at":"2023-06-28T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2023-07-10","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Michael Favet resigned as Director at NeuroPace Inc.","evidence_excerpt":"On June 27, 2023, Michael Favet resigned from his position as Chief Executive Officer of NeuroPace, Inc. and as a member of NeuroPace’s board of directors","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-177492","anchor_url":"https://secwatch.observer/filing/0001193125-23-177492#claim-2c239bcc1c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1528287/000119312523177492/0001193125-23-177492-index.htm"},{"fact_type":"executive_change","fact_key":"4922324e67","cik":1528287,"ticker":"NPCE","company_name":"NeuroPace Inc","filed_at":"2023-06-28T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2023-07-10","interim":false,"role":"Chief Executive Officer","role_category":"ceo","successor_name":"Joel Becker","successor_named":true},"claim":"Michael Favet resigned as Chief Executive Officer at NeuroPace Inc.","evidence_excerpt":"On June 27, 2023, Michael Favet resigned from his position as Chief Executive Officer of NeuroPace, Inc. and as a member of NeuroPace’s board of directors","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-177492","anchor_url":"https://secwatch.observer/filing/0001193125-23-177492#claim-4922324e67","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1528287/000119312523177492/0001193125-23-177492-index.htm"},{"fact_type":"shareholder_vote","fact_key":"c1eba4486e6fc5ffed484431e7c579436e96d997","cik":1528287,"ticker":"NPCE","company_name":"NeuroPace Inc","filed_at":"2023-06-12T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-07","outcome":"passed","proposal_text":"Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"11,989","votes_against":"9,012","votes_for":"16,456,369","votes_withheld":null}]},"claim":"NeuroPace Inc shareholders approved Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm at the 2023-06-07 meeting.","evidence_excerpt":"NeuroPace’s stockholders ratified the appointment of PricewaterhouseCoopers LLP as NeuroPace’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The results of the vote were: For Against Abstain Broker Non-Votes 16,456,369 9,012 11,989 0","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001528287-23-000028","anchor_url":"https://secwatch.observer/filing/0001528287-23-000028#claim-c1eba4486e6fc5ffed484431e7c579436e96d997","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1528287/000152828723000028/0001528287-23-000028-index.htm"},{"fact_type":"shareholder_vote","fact_key":"853a5e6c4b35abcb74d96f41bdcee6262f769564","cik":1528287,"ticker":"NPCE","company_name":"NeuroPace Inc","filed_at":"2023-06-12T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-07","outcome":"passed","proposal_text":"Election of Class II directors","proposal_type":"director_election","results":[{"broker_non_votes":"7,538,467","subject":"Lisa Andrade","votes_abstain":null,"votes_against":null,"votes_for":"8,506,611","votes_withheld":"432,292"},{"broker_non_votes":"7,538,467","subject":"Joseph Lacob","votes_abstain":null,"votes_against":null,"votes_for":"8,475,094","votes_withheld":"463,809"}]},"claim":"NeuroPace Inc shareholders approved Election of Class II directors at the 2023-06-07 meeting.","evidence_excerpt":"NeuroPace’s stockholders elected each of the following Class II director nominees to hold office until NeuroPace’s 2026 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified or until his or her earlier death, resignation, or removal. The results of the vote were: Nominee For Withhold Broker Non-Votes Lisa Andrade 8,506,611 432,292 7,538,467 Joseph Lacob 8,475,094 463,809 7,538,467","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001528287-23-000028","anchor_url":"https://secwatch.observer/filing/0001528287-23-000028#claim-853a5e6c4b35abcb74d96f41bdcee6262f769564","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1528287/000152828723000028/0001528287-23-000028-index.htm"},{"fact_type":"earnings_release","fact_key":"1bac80aa409a91c658355b3bf400294f4085a306","cik":1528287,"ticker":"NPCE","company_name":"NeuroPace Inc","filed_at":"2023-05-04T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"full year 2023","report_date":"2023-05-04","result_type":"guidance_update","revenue_text":"$52 million to $54 million"},"claim":"NeuroPace Inc reported full year 2023 results: revenue $52 million to $54 million. Guidance raised.","evidence_excerpt":"Full Year 2023 Financial Guidance • Increased total revenue guidance to $52 million to $54 million, representing growth of 14% to 19% over 2022, as compared to previously-communicated guidance of $50 million to $52 million • Reiterated gross margin to range between 69% and 71% • Reiterated total operating expenses to range between $75 million and $77 million","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001528287-23-000024","anchor_url":"https://secwatch.observer/filing/0001528287-23-000024#claim-1bac80aa409a91c658355b3bf400294f4085a306","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1528287/000152828723000024/0001528287-23-000024-index.htm"},{"fact_type":"earnings_release","fact_key":"6749ff633573022a5a16a93e459319991df27b24","cik":1528287,"ticker":"NPCE","company_name":"NeuroPace Inc","filed_at":"2023-05-04T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$10.4 million","period_text":"first quarter ended March 31, 2023","report_date":"2023-05-04","result_type":"reported_results","revenue_text":"$14.5 million"},"claim":"NeuroPace Inc reported first quarter ended March 31, 2023 results: revenue $14.5 million, net income $10.4 million.","evidence_excerpt":"Total revenue was $14.5 million in the first quarter of 2023, representing growth of 27% compared to the prior year period and 13% compared to the prior quarter. Replacement implant revenue declined compared to the prior year period and represented less than 10% of total revenue in the first quarter of 2023. The decrease in replacement implant revenue was expected as previously implanted patients finish transitioning to the second generation RNS System with a nearly 11-year average battery life. Gross margin for the first quarter of 2023 was 72% compared to 73% in the first quarter of 2022 and 69% in the fourth quarter of 2022. The decline in gross margin compared to the first quarter of 2022 was primarily due to the change in product mix as a result of initiating distribution of DIXI Medical products in the fourth quarter of 2022. Total operating expenses in the first quarter of 2023 were $18.7 million, compared to $18.0 million in the prior year period. R&D expense in the first quart","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001528287-23-000024","anchor_url":"https://secwatch.observer/filing/0001528287-23-000024#claim-6749ff633573022a5a16a93e459319991df27b24","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1528287/000152828723000024/0001528287-23-000024-index.htm"},{"fact_type":"executive_change","fact_key":"bf0afc4100","cik":1528287,"ticker":"NPCE","company_name":"NeuroPace Inc","filed_at":"2023-04-13T23:59:59+00:00","payload":{"action":"will not stand for reelection","action_category":"departure","departure_tone":"routine","effective_date":null,"interim":false,"role":"director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Greg Garfield departed as director at NeuroPace Inc.","evidence_excerpt":"On April 11, 2023, Greg Garfield notified NeuroPace, Inc. that he will not stand for reelection as a director to the Board of Directors (the “Board”) of NeuroPace, Inc.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-100628","anchor_url":"https://secwatch.observer/filing/0001193125-23-100628#claim-bf0afc4100","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1528287/000119312523100628/0001193125-23-100628-index.htm"},{"fact_type":"earnings_release","fact_key":"1d75747115e27bd34ff61ccd0eb7de7dad53ddb1","cik":1528287,"ticker":"NPCE","company_name":"NeuroPace Inc","filed_at":"2023-03-02T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"initiated","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"Full Year 2023","report_date":"2023-03-02","result_type":"guidance_update","revenue_text":null},"claim":"NeuroPace Inc updated its Full Year 2023 guidance (initiated).","evidence_excerpt":"Full Year 2023 Financial Guidance • Total revenue to range between $50.0 million to $52.0 million, growing approximately 10% to 14% over 2022 • Gross margin to range between 69% to 71% • Total operating expenses to range between $75.0 million to $77.0 million","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001528287-23-000005","anchor_url":"https://secwatch.observer/filing/0001528287-23-000005#claim-1d75747115e27bd34ff61ccd0eb7de7dad53ddb1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1528287/000152828723000005/0001528287-23-000005-index.htm"},{"fact_type":"earnings_release","fact_key":"77b2a64916f6c6564f803ddde5ee5a6c1dc04969","cik":1528287,"ticker":"NPCE","company_name":"NeuroPace Inc","filed_at":"2023-03-02T23:59:59+00:00","payload":{"eps_text":"not provided","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the full year ended December 31, 2022","report_date":"2023-03-02","result_type":"reported_results","revenue_text":null},"claim":"NeuroPace Inc reported the full year ended December 31, 2022 results: EPS not provided.","evidence_excerpt":"On March 2, 2023, NeuroPace, Inc. issued a press release announcing its financial results for the fiscal quarter and full year ended December 31, 2022.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001528287-23-000005","anchor_url":"https://secwatch.observer/filing/0001528287-23-000005#claim-77b2a64916f6c6564f803ddde5ee5a6c1dc04969","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1528287/000152828723000005/0001528287-23-000005-index.htm"},{"fact_type":"earnings_release","fact_key":"85f7e32da51e27d8e539de3babfa353d2697595c","cik":1528287,"ticker":"NPCE","company_name":"NeuroPace Inc","filed_at":"2023-03-02T23:59:59+00:00","payload":{"eps_text":"not provided","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fourth quarter ended December 31, 2022","report_date":"2023-03-02","result_type":"reported_results","revenue_text":null},"claim":"NeuroPace Inc reported the fourth quarter ended December 31, 2022 results: EPS not provided.","evidence_excerpt":"On March 2, 2023, NeuroPace, Inc. issued a press release announcing its financial results for the fiscal quarter and full year ended December 31, 2022.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001528287-23-000005","anchor_url":"https://secwatch.observer/filing/0001528287-23-000005#claim-85f7e32da51e27d8e539de3babfa353d2697595c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1528287/000152828723000005/0001528287-23-000005-index.htm"},{"fact_type":"earnings_release","fact_key":"84a9ec8e1b504e5230e45c59fdb028962bca5b77","cik":1528287,"ticker":"NPCE","company_name":"NeuroPace Inc","filed_at":"2023-01-09T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"fiscal quarter and year ended December 31, 2022","report_date":"2023-01-09","result_type":"preliminary_results","revenue_text":"approximately $12.8 million"},"claim":"NeuroPace Inc reported fiscal quarter and year ended December 31, 2022 results: revenue approximately $12.8 million.","evidence_excerpt":"December 31, 2022 and\nthe appointment of Dr. Uri Geiger to its Board of Directors. Preliminary Unaudited Fourth Quarter 2022 • Total revenue is expected to be approximately $12.8 million, representing growth of 16% compared to\n$11.0 million in the fourth quarter of 2021. • Initial implant revenue is expected to be approximately $9.8 million, representing growth","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-004750","anchor_url":"https://secwatch.observer/filing/0001193125-23-004750#claim-84a9ec8e1b504e5230e45c59fdb028962bca5b77","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1528287/000119312523004750/0001193125-23-004750-index.htm"},{"fact_type":"executive_change","fact_key":"dd10f4f944","cik":1528287,"ticker":"NPCE","company_name":"NeuroPace Inc","filed_at":"2023-01-09T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-01-05","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Dr. Uri Geiger was appointed as Director at NeuroPace Inc.","evidence_excerpt":"On January 4, 2023, the NeuroPace Board appointed Dr. Uri Geiger as a Class III director, effective as of January 5, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-004750","anchor_url":"https://secwatch.observer/filing/0001193125-23-004750#claim-dd10f4f944","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1528287/000119312523004750/0001193125-23-004750-index.htm"},{"fact_type":"earnings_release","fact_key":"8f60e9d5623cd4321af4a4e8fcccf542a4e7b806","cik":1528287,"ticker":"NPCE","company_name":"NeuroPace Inc","filed_at":"2022-11-08T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":"$11.8 million","period_text":"the quarter ending September 30, 2022","report_date":"2022-11-08","result_type":"reported_results","revenue_text":"$11.2 million"},"claim":"NeuroPace Inc reported the quarter ending September 30, 2022 results: revenue $11.2 million, net income $11.8 million. Guidance raised.","evidence_excerpt":"the lives of people suffering from epilepsy, today reported financial results for the quarter ending September 30, 2022. Recent Highlights • Achieved total revenue of $11.2 million for the third quarter of 2022, representing growth of 8% compared to the third quarter of 2021 and 9% compared to the second quarter of 2022 • Achieved initial implant revenue of","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001528287-22-000026","anchor_url":"https://secwatch.observer/filing/0001528287-22-000026#claim-8f60e9d5623cd4321af4a4e8fcccf542a4e7b806","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1528287/000152828722000026/0001528287-22-000026-index.htm"},{"fact_type":"executive_change","fact_key":"3bed39d7b1","cik":1528287,"ticker":"NPCE","company_name":"NeuroPace Inc","filed_at":"2021-10-19T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2021-11-01","interim":false,"role":"Class II director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Lisa Andrade was appointed as Class II director at NeuroPace Inc.","evidence_excerpt":"On October 15, 2021, the Board appointed Lisa Andrade as a Class II director to fill the vacancy created by Mr. Norton’s resignation, effective as of November 1, 2021.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-21-302022","anchor_url":"https://secwatch.observer/filing/0001193125-21-302022#claim-3bed39d7b1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1528287/000119312521302022/0001193125-21-302022-index.htm"},{"fact_type":"executive_change","fact_key":"8dc1e68c23","cik":1528287,"ticker":"NPCE","company_name":"NeuroPace Inc","filed_at":"2021-10-19T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2021-11-01","interim":false,"role":"Class II director","role_category":"director","successor_name":"Lisa Andrade","successor_named":true},"claim":"Evan Norton resigned as Class II director at NeuroPace Inc.","evidence_excerpt":"On October 14, 2021, Evan Norton, a Class II director, resigned from the Board of Directors (the “Board”) (including the Compensation Committee and Audit Committee) of NeuroPace, Inc., effective as of November 1, 2021.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-21-302022","anchor_url":"https://secwatch.observer/filing/0001193125-21-302022#claim-8dc1e68c23","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1528287/000119312521302022/0001193125-21-302022-index.htm"}]}